With a CAGR of 5.8%, the worldwide osteoporosis testing market is expected to rise from USD 2.1 billion in 2022 to USD 3.9 billion by 2031. Over the projected period, North America is predicted to control the market.
Rising osteoporosis prevalence worldwide, particularly among the aging population, is driving notable increase in the osteoporosis testing market. Market growth is driven by growing knowledge of early diagnosis and prevention of osteoporosis as well as by technological developments in bone densitometry techniques. Furthermore projected to open fresh prospects for market competitors are the increasing acceptance of point-of-care testing and the integration of artificial intelligence in diagnostic instruments.
Market Trend: Integration of artificial intelligence for osteoporosis diagnosis
One important trend in the market is the integration of artificial intelligence (AI) in osteoporosis diagnosis. Developed to improve the accuracy and efficiency of bone density tests and fracture risk assessments, AI algorithms These AI-powered technologies can examine difficult imaging data—including CT pictures and DXA scans—to offer more exact diagnosis and treatment advice. Large datasets are being used for training machine learning models to find subtle patterns and signs of bone loss maybe undetected by human observers. Along with increasing osteoporosis test sensitivity and specificity, this trend is helping to standardize interpretations in many diverse healthcare environments. Predictive models developed using artificial intelligence can allow one to evaluate their future fracture risk depending on imaging findings, clinical data, and genetic information. Personalized osteoporosis management and treatment planning should benefit from these technologies' ongoing evolution in increasingly significant ways.
Market Driver: Increasing geriatric population and osteoporosis frequency
The market for osteoporosis testing is mostly driven by the global growing geriatric population. People's risk of osteoporosis and accompanying fractures increases greatly as they get older. The World Health Organisation estimates that, more than doubling from 900 million in 2015, the global population aged 60 years and above would reach 2 billion by 2025. This demographic change is increasing osteoporosis prevalence and driving more need for diagnostic tools. Because of things like hormonal changes, less physical activity, and lower calcium absorption, older folks are more prone to bone loss. Moreover, demand for bone density tests and other diagnostic techniques is resulting from this population's increasing knowledge of the need of early identification and prevention of osteoporosis. Preventive treatment for the elderly—which includes frequent osteoporosis screening—is underlined by healthcare systems all around. Early detection is not only improving patient outcomes but also driving market expansion as more people seek testing facilities.
Market Restraint: Bone Densitometry rules the test type segment
Particularly Dual-energy X-ray Absorptiometry (DXA), Bone densitometry rules the portion of the osteoporosis testing market dedicated to test type. Because of its great accuracy, minimal radiation dose, and capacity to detect bone density at several skeletal locations, DXA is generally agreed upon as the gold standard for osteoporosis diagnosis and fracture risk assessment. Patients and medical professionals alike like the non-invasive character of the procedure and rather short scanning times. Excellent for tracking disease development and therapy efficacy, DXA scans offer comprehensive information about bone mineral density (BMD) and can identify even minute changes in bone mass over time. DXA technology's commercial domination can be greatly attributed to its broad acceptance in hospitals, diagnostic centers, and specialist clinics. Furthermore improving DXA systems' clinical value and preserving their leadership position in the field of osteoporosis diagnostics are continuous technological developments like the incorporation of 3D imaging capabilities and body composition analysis. Bone densitometry tests' demand has also been fueled by the growing awareness of osteoporosis as a major public health issue and the increasing emphasis on preventive healthcare, therefore confirming their role as the main diagnostic tool in osteoporosis management.
Bone Densitometry dominates the test type segment
Bone densitometry, particularly Dual-energy X-ray Absorptiometry (DXA), dominates the test type segment in the osteoporosis testing market. DXA is widely considered the gold standard for diagnosing osteoporosis and assessing fracture risk due to its high accuracy, low radiation exposure, and ability to measure bone density at multiple skeletal sites. The technique's non-invasive nature and relatively quick scanning time make it preferred by both healthcare providers and patients. DXA scans provide detailed information about bone mineral density (BMD) and can detect even small changes in bone mass over time, making them invaluable for monitoring disease progression and treatment efficacy. The widespread adoption of DXA technology in hospitals, diagnostic centers, and specialty clinics has significantly contributed to its market dominance. Additionally, ongoing technological advancements in DXA systems, such as the integration of 3D imaging capabilities and body composition analysis, are further enhancing its clinical utility and maintaining its leadership position in the osteoporosis testing landscape. The increasing focus on preventive healthcare and the growing recognition of osteoporosis as a major public health concern have also driven the demand for bone densitometry tests, solidifying their position as the primary diagnostic tool in osteoporosis management.
Osteoporosis testing market leader North America
Currently leading the worldwide osteoporosis testing market, North America is likely to hold this position all through the forecast period. The region's high incidence of osteoporosis, established healthcare system, and sophisticated diagnostic tools help to explain this dominance. Particularly the United States has a sizable aging population; low bone mass causes another 44 million people to be at risk while osteoporosis affects about 10 million people. Regular bone density screening programs have been widely embraced in the area due of their great emphasis on early illness identification and preventative healthcare. Furthermore, good reimbursement rules for osteoporosis testing in the United States and Canada have greatly expanded availability of these diagnostic tools. Major participants in the industry and continuous research and development activities in the area still inspire creativity in osteoporosis testing methods. Moreover, North America's leadership in this market is influenced by high healthcare expenditure, growing awareness of bone health, and proactive government projects meant to lower the load of osteoporosis-related fractures. The excellent healthcare IT system of the area also helps to integrate digital health solutions and AI-powered diagnostic tools, therefore improving the accuracy and efficiency of osteoporosis testing programs.
Strong rivalry among important players in the osteoporosis testing industry drives each one to innovate and increase their share of the market. To get a competitive edge, big businesses are concentrating on technological developments, especially in biomarker testing and bone densitometry equipment. Seeking to increase their product lines and geographical footprint, companies often engage in strategic alliances, mergers, and acquisitions. Developing point-of-care testing solutions and combining AI-powered diagnostic tools to improve accuracy and efficiency are under more and more importance. Particularly in developing countries, regional firms are also significantly contributing by providing reasonably priced solutions catered to local healthcare need. Particularly in fields like genetic testing for osteoporosis risk assessment, the industry is witnessing growing investment in research and development. To better their market positions, companies are also concentrating on growing their distribution networks and enhancing after-sales services. Growing knowledge of osteoporosis prevention drives a trend toward complete bone health management systems combining monitoring and treatment choices with diagnostic instruments.
GE Healthcare
Hologic Inc.
DMS Imaging
Swissray International Inc.
BeamMed Ltd.
Osteosys Co. Ltd.
Diagnostic Medical Systems Group
Medonica Co. Ltd.
Osteometer MediTech Inc.
Scanflex Healthcare AB
FURUNO ELECTRIC CO., LTD.
Xianyang Kanrota Digital Ultrasound System Co. Ltd.
1. INTRODUCTION
1.1. Market Definition
1.2. Study Scope
1.3. Currency Conversion
1.4. Study Period (2022- 2031)
1.5. Regional Coverage
2. RESEARCH METHODOLOGY
2.1. Primary Research
2.2. Secondary Research
2.3. Company Share Analysis
2.4. Data Triangulation
3. EXECUTIVE SUMMARY
3.1. Global Osteoporosis Testing Market (2018 – 2022)
3.2. Global Osteoporosis Testing Market (2023 – 2031)
3.2.1. Market Segment By Test Type (2023 – 2031)
3.2.2. Market Segment By End User (2023 – 2031)
3.2.3. Market Segment By Region (2023 – 2031)
4. MARKET DYNAMICS
4.1. Market Trends
4.1.1. Integration of AI in osteoporosis diagnostics
4.1.2. Rise of point-of-care testing for osteoporosis
4.1.3. Increasing focus on personalized medicine in bone health
4.2. Market Drivers
4.2.1. Increasing geriatric population and osteoporosis prevalence
4.2.2. Technological advancements in bone densitometry techniques
4.2.3. Growing awareness about early diagnosis and prevention
4.3. Market Restraints
4.3.1. High costs associated with advanced diagnostic technologies
4.3.2. Limited access to testing in developing regions
4.4. Porter's Five Forces Analysis
4.4.1. Threat of New Entrants
4.4.2. Bargaining Power of Buyers/Consumers
4.4.3. Bargaining Power of Suppliers
4.4.4. Threat of Substitute Products
4.4.5. Intensity of Competitive Rivalry
4.5. Supply Chain Analysis
4.6. Pricing Analysis
4.7. Regulatory Analysis
4.8. Pipeline Analysis
5. BY TEST TYPE (MARKET VALUE (US$ MILLION) – 2022-2031*)
5.1. Bone Densitometry
5.2. Biomarkers
5.3. Others
6. BY END USER
6.1. Hospitals
6.2. Diagnostic Centers
6.3. Specialty Clinics
6.4. Others
7. GEOGRAPHY
7.1. North America
7.1.1. United States
7.1.2. Canada
7.1.3. Mexico
7.2. South America
7.2.1. Brazil
7.2.2. Argentina
7.2.3. Rest of South America
7.3. Europe
7.3.1. Germany
7.3.2. United Kingdom
7.3.3. France
7.3.4. Italy
7.3.5. Spain
7.3.6. Russia
7.3.7. Rest of Europe
7.4. Asia-Pacific
7.4.1. China
7.4.2. Japan
7.4.3. India
7.4.4. Australia
7.4.5. South Korea
7.4.6. Rest of Asia-Pacific
7.5. Middle-East
7.5.1. UAE
7.5.2. Saudi Arabia
7.5.3. Turkey
7.5.4. Rest of Middle East
7.6. Africa
7.6.1. South Africa
7.6.2. Egypt
7.6.3. Rest of Africa
8. COMPETITIVE LANDSCAPE
8.1. Key Developments
8.2. Company Market Share Analysis
8.3. Product Benchmarking
9. SWOT ANALYSIS
10. COMPANY PROFILES
10.1. GE Healthcare
10.2. Hologic Inc.
10.3. DMS Imaging
10.4. Swissray International Inc.
10.5. BeamMed Ltd.
10.6. Osteosys Co. Ltd.
10.7. Diagnostic Medical Systems Group
10.8. Medonica Co. Ltd.
10.9. Osteometer MediTech Inc.
10.10. Scanflex Healthcare AB
10.11. FURUNO ELECTRIC CO., LTD.
10.12. Xianyang Kanrota Digital Ultrasound System Co. Ltd. (*LIST NOT EXHAUSTIVE)
11. MARKET OPPORTUNITIES
Bone Densitometry
Biomarkers
Others
By End User:
Hospitals
Diagnostic Centers
Specialty Clinics
Others
By Region:
North America
Europe
Asia-Pacific
Latin America
Middle East & Africa
We at Aurorawave Intellects Market Report gives total market analysis that suit our customer business need and permit decision maker to run organizations without any problem. We have accomplished greatness in giving start to finish market research arrangements. Our detachment of industry specialists accumulate key data and get ready substance that lines up with our customer's business/specialty.
We at aurorawaveintellects.com offer mainly 3 types of licenses:
• Single User: Research Report copy can be distributed to a single user only
• Multi User: Research Report distribution is restricted up to 5 users.
• Corporate License :Research Report can be distributed across the company.
Based on the nature of the topic or research, the formats vary. The different formats of the report are as following:
• Word Document
• PPT
Following modes are available for making the payment:
• Online Payment (Visa Card, Master Card, Stripe)
• Razorpay
• Net Banking
• Bank Wire Transfer
Our customer service and research specialist team are available by phone and by email. Customer service hours are 24X7 Indian Standard Time (IST). You may reach us at:
• Email: info@aurorawaveintellects.com
• United Kingdom: ++91 7382742511
